Haleon Contemplates Sale of Non-Core Businesses, Including Nicotinell Brand: A Strategy Shift Towards Core Products
Portfolio Pulse from Vandana Singh
Haleon Plc (NYSE:HLN) is considering selling some non-core businesses, including its Nicotinell brand, as part of a strategy shift towards core products. The sale of Nicotinell could be valued as high as $800 million. Haleon was formed from the demerger of GSK plc's (NYSE:GSK) Consumer Healthcare business. GSK recently sold 240 million Haleon shares, reducing its stake to 10.3%. Unilever plc (NYSE:UL) has made three unsolicited proposals to acquire GSK's Consumer Healthcare business.
July 05, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
GSK has reduced its stake in Haleon and received unsolicited proposals from Unilever to acquire its Consumer Healthcare business.
GSK's reduction of its stake in Haleon and the unsolicited proposals from Unilever could potentially impact GSK's stock price, but it's unclear how this will play out in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Haleon is considering selling non-core businesses, which could potentially bring in significant revenue.
The sale of non-core businesses could bring in significant revenue for Haleon, but it's unclear how this will impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Unilever has made three unsolicited proposals to acquire GSK's Consumer Healthcare business.
Unilever's proposals to acquire GSK's Consumer Healthcare business could potentially impact Unilever's stock price, but it's unclear how this will play out in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60